Form 4 Filing for BioXcel Therapeutics, Inc.

This filing details stock transactions by Javier Rodriguez, Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics, Inc. On June 15, 2026, Rodriguez acquired 35 shares of Common Stock (transaction code M, acquired code A) and was granted 35 Restricted Stock Units (RSUs) which represent a contingent right to receive one share of Common Stock each. These RSUs are subject to a vesting schedule starting on the first anniversary of March 15, 2023, with 25% vesting then, and 6.25% every three months thereafter, contingent upon continued employment. The reported transactions do not involve any monetary price, as indicated by a price of 0.0 for both the acquired shares and the RSUs. Following these transactions, Rodriguez holds 26,838 shares of Common Stock directly and has 212 RSUs remaining.